⌘K

Login Start Free

Home/Filings/4/0001415889-25-023550

4//SEC Filing

Patel Sanj K 4

Accession 0001415889-25-023550

CIK 0001730430other

View on SEC.gov Company Profile

Filed

Sep 2, 8:00 PM ET

Accepted

Sep 3, 4:44 PM ET

Size

26.9 KB

Accession

0001415889-25-023550

Insider Transaction Report

Form 4

Period: 2025-09-01

Kiniksa Pharmaceuticals International, plcKNSA

DirectorCHAIRMAN & CEO

Transactions

Tax Payment
Class A Ordinary Share
2025-09-01$33.49/sh−10,983$367,821→ 108,402 total
Exercise/Conversion
Class A Ordinary Share
2025-09-01+6,238→ 102,912 total
Exercise/Conversion
Class A Ordinary Share
2025-09-02+6,569→ 114,971 total
Award
Restricted Share Unit
2025-09-01+34,435→ 34,435 total
→ Class A Ordinary Share (34,435 underlying)
Exercise/Conversion
Restricted Share Unit
2025-09-01−6,481→ 12,962 total
→ Class A Ordinary Share (6,481 underlying)
Tax Payment
Class A Ordinary Share
2025-09-02$34.28/sh−3,177$108,908→ 111,794 total
Exercise/Conversion
Restricted Share Unit
2025-09-01−6,238→ 18,712 total
→ Class A Ordinary Shares (6,238 underlying)
Exercise/Conversion
Restricted Share Unit
2025-09-01−9,992→ 9,991 total
→ Class A Ordinary Share (9,992 underlying)
Exercise/Conversion
Class A Ordinary Share
2025-09-01+6,481→ 109,393 total
Exercise/Conversion
Restricted Share Unit
2025-09-02−6,569→ 0 total
→ Class A Ordinary Share (6,569 underlying)
Exercise/Conversion
Class A Ordinary Share
2025-09-01+9,992→ 119,385 total
Award
Share Option
2025-09-01+137,638→ 137,638 total
Exercise: $33.49Exp: 2035-08-31→ Class A Ordinary Share (137,638 underlying)

Holdings

Class A Ordinary Share
(indirect: By Trust)
109,795

Footnotes (7)

[F1]Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
[F2]The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2025.
[F3]The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2025.
[F4]The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2024.
[F5]The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023.
[F6]The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022.
[F7]The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021.

Documents

1 file

4
form4-09032025_080927.xmlPrimary

Issuer

Kiniksa Pharmaceuticals International, plc

CIK 0001730430

Entity typeother

Related Parties

1

filerCIK 0001532218

Filing Metadata

Form type: 4
Filed: Sep 2, 8:00 PM ET
Accepted: Sep 3, 4:44 PM ET
Size: 26.9 KB

View on SEC.gov